Codexis Inc Market Cap ($107.49 Million)
Market Cap & Net Worth: Codexis Inc (CDXS)
Codexis Inc market cap. Codexis Inc (NASDAQ:CDXS) has a market capitalization of $107.49 Million ($107.49 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18727 globally and #4353 in its home market, demonstrating a -9.16% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Codexis Inc's stock price $1.19 by its total outstanding shares 90324383 (90.32 Million). Also see Codexis Inc (CDXS) cash conversion ratio for how efficiently the company converts equity into cash flow.
Codexis Inc Market Cap History (2015–2026)
Codexis Inc market cap history from 2015 to 2026. Data shows change from $382.07 Million to $107.49 Million (-8.52% CAGR). Check CDXS stock price and chart for real-time trading data and today's change.
Index Memberships
Codexis Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #513 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #1794 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.01% | #235 of 263 |
Weight: Codexis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Codexis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Codexis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CDXS year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.26x
Codexis Inc's market cap is 7.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $382.07 Million | $41.80 Million | -$7.58 Million | 9.14x | N/A |
| 2016 | $415.49 Million | $48.84 Million | -$8.56 Million | 8.51x | N/A |
| 2017 | $754.21 Million | $50.02 Million | -$23.00 Million | 15.08x | N/A |
| 2018 | $1.51 Billion | $60.59 Million | -$10.88 Million | 24.89x | N/A |
| 2019 | $1.44 Billion | $68.46 Million | -$11.94 Million | 21.10x | N/A |
| 2020 | $1.97 Billion | $69.06 Million | -$24.01 Million | 28.55x | N/A |
| 2021 | $2.82 Billion | $104.75 Million | -$21.28 Million | 26.96x | N/A |
| 2022 | $420.91 Million | $138.59 Million | -$33.59 Million | 3.04x | N/A |
| 2023 | $275.49 Million | $70.14 Million | -$76.24 Million | 3.93x | N/A |
| 2024 | $430.85 Million | $59.34 Million | -$65.28 Million | 7.26x | N/A |
Competitor Companies of CDXS by Market Capitalization
Companies near Codexis Inc in the global market cap rankings as of November 1, 2026. Also see CDXS current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Codexis Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Codexis Inc (2015–2026)
Market capitalization of Codexis Inc from 2015 to today. Between 2015 and today, Codexis Inc's market cap moved from $382.07 Million to $ 107.49 Million, with a yearly change of -8.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $107.49 Million | -26.99% |
| 2025 | $147.23 Million | -65.83% |
| 2024 | $430.85 Million | +56.39% |
| 2023 | $275.49 Million | -34.55% |
| 2022 | $420.91 Million | -85.10% |
| 2021 | $2.82 Billion | +43.24% |
| 2020 | $1.97 Billion | +36.52% |
| 2019 | $1.44 Billion | -4.25% |
| 2018 | $1.51 Billion | +100.00% |
| 2017 | $754.21 Million | +81.52% |
| 2016 | $415.49 Million | +8.75% |
| 2015 | $382.07 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Codexis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $107.49 Million USD |
| MoneyControl | $107.49 Million USD |
| MarketWatch | $107.49 Million USD |
| marketcap.company | $107.49 Million USD |
| Reuters | $107.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Codexis Inc
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the … Read more